Literature DB >> 19337840

Hematologic neoplasias and acromegaly.

Flavia Regina P Barbosa1, Leonardo Vieira Neto, Giovanna Aparecida B Lima, Luiz Eduardo Wildemberg, Rodrigo Portugal, Monica R Gadelha.   

Abstract

We report a 59-year-old acromegalic woman, who presented with generalized bone pain, weakness, fatigue and foamy urine, who was found to have multiple myeloma (MM); and a 60-year-old acromegalic woman with dizziness, vomiting and abdominal pain, high blood pressure and splenomegaly that was posteriorly diagnosed as having Waldenstrom's macroglobulinemia (WM). Acromegaly is an uncommon disease and epidemiological studies have provided increasingly debated evidence that elevated IGF-I levels might enhance the neoplastic risk, and that cancers constitute the third leading cause of mortality in acromegaly. It is known that GH and IGF-I can activate B cell lymphocytes, and that IGF-I receptor is universally expressed in MM cells. Although the complication of acromegaly with WM or MM in patients has rarely been reported until now, we described two case reports of acromegalic patients with those hematological neoplasias, which allow a discussion about this controversial issue.

Entities:  

Mesh:

Year:  2011        PMID: 19337840     DOI: 10.1007/s11102-009-0176-0

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  46 in total

1.  Insulin-like growth factor I is a dual effector of multiple myeloma cell growth.

Authors:  N L Ge; S Rudikoff
Journal:  Blood       Date:  2000-10-15       Impact factor: 22.113

2.  Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984.

Authors:  B A Bengtsson; S Edén; I Ernest; A Odén; B Sjögren
Journal:  Acta Med Scand       Date:  1988

Review 3.  The role of growth hormone and insulin-like growth factors in the immune system.

Authors:  S C van Buul-Offers; R Kooijman
Journal:  Cell Mol Life Sci       Date:  1998-10       Impact factor: 9.261

Review 4.  Acromegaly.

Authors:  S Melmed
Journal:  N Engl J Med       Date:  1990-04-05       Impact factor: 91.245

Review 5.  The epidemiology of multiple myeloma.

Authors:  D A Riedel; L M Pottern
Journal:  Hematol Oncol Clin North Am       Date:  1992-04       Impact factor: 3.722

6.  Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk.

Authors:  Eva S Schernhammer; Jeff M Holly; Michael N Pollak; Susan E Hankinson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-03       Impact factor: 4.254

7.  Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice.

Authors:  G Lattanzio; C Libert; M Aquilina; M Cappelletti; G Ciliberto; P Musiani; V Poli
Journal:  Am J Pathol       Date:  1997-09       Impact factor: 4.307

8.  Acromegaly and non-Hodgkin's lymphoma.

Authors:  R H Alves; M Vaisman; R R Brasil; M R Gadelha
Journal:  Endocr Pract       Date:  1998 Sep-Oct       Impact factor: 3.443

9.  Interleukin-6 in multiple myeloma: correlation with disease activity and Ki-67 proliferation index.

Authors:  J Thaler; F Fechner; M Herold; H Huber
Journal:  Leuk Lymphoma       Date:  1994-01

10.  Insulin-like growth factor-I regulates pro-B cell differentiation.

Authors:  K S Landreth; R Narayanan; K Dorshkind
Journal:  Blood       Date:  1992-09-01       Impact factor: 22.113

View more
  2 in total

1.  Clinical manifestations and diagnosis of acromegaly.

Authors:  Gloria Lugo; Lara Pena; Fernando Cordido
Journal:  Int J Endocrinol       Date:  2012-02-01       Impact factor: 3.257

2.  Multiple myeloma in a patient with acromegaly.

Authors:  Yu Mi Kang; Jong Han Choi; Min Jung Lee; Ari Ahn; Chan Jeoung Park; Kiju Chang; Seyoung Seo; Sun In Hong; Min Seon Kim
Journal:  Endocrinol Metab (Seoul)       Date:  2014-08-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.